• Something wrong with this record ?

Safety and diagnostic efficacy of gadoteridol for magnetic resonance imaging of the brain and spine in children 2 years of age and younger

CC. Shah, MV. Spampinato, HA. Parmar, OA. Raslan, P. Tomà, DDM. Lin, J. Vymazal, C. Colosimo, DS. Enterline

. 2021 ; 51 (10) : 1895-1906. [pub] 20210505

Language English Country Germany

Document type Journal Article

E-resources Online Full text

NLK ProQuest Central from 1997-01-01 to 1 year ago
CINAHL Plus with Full Text (EBSCOhost) from 2008-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2000-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest) from 1997-01-01 to 1 year ago
Health & Medicine (ProQuest) from 1997-01-01 to 1 year ago
Family Health Database (ProQuest) from 1997-01-01 to 1 year ago

BACKGROUND: Neonates and young children require efficacious magnetic resonance imaging (MRI) examinations but are potentially more susceptible to the short- and long-term adverse effects of gadolinium-based contrast agents due to the immaturity of their body functions. OBJECTIVE: To evaluate the acute safety and diagnostic efficacy of gadoteridol (ProHance) for contrast-enhanced MRI of the central nervous system (CNS) in children ≤2 years of age. MATERIALS AND METHODS: One hundred twenty-five children ≤2 years old (including 57 children <6 months old) who underwent contrast-enhanced MRI of the CNS with gadoteridol at 0.1 mmol/kg body weight were retrospectively enrolled at five imaging centers. Safety data were assessed for acute/subacute adverse events in the 48 h following gadoteridol administration and, when available, vital signs, electrocardiogram (ECG) and clinical laboratory values obtained from blood samples taken from 48 h before until 48 h following the MRI exam. The efficacy of gadoteridol-enhanced MRI compared to unenhanced MRI for disease diagnosis was evaluated prospectively by three blinded, unaffiliated readers. RESULTS: Thirteen changes of laboratory values (11 mild, 1 moderate, 1 unspecified) were reported as adverse events in 7 (5.6%) patients. A relationship to gadoteridol was deemed possible though doubtful for two of these adverse events in two patients (1.6%). There were no clinical adverse events, no serious adverse events and no clinically meaningful changes in vital signs or ECG recordings. Accurate differentiation of tumor from non-neoplastic disease, and exact matching of specific MRI-determined diagnoses with on-site final diagnoses, was achieved in significantly more patients by each reader following the evaluation of combined pre- and post-contrast images compared to pre-contrast images alone (84.6-88.0% vs. 70.9-76.9%; P≤0.006 and 67.5-79.5% vs. 47.0-66.7%; P≤0.011, respectively). CONCLUSION: Gadoteridol at 0.1 mmol/kg body weight is safe, well tolerated and effective for contrast-enhanced MRI of the CNS in children ≤2 years of age.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003857
003      
CZ-PrNML
005      
20220127145804.0
007      
ta
008      
220113s2021 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00247-021-05069-w $2 doi
035    __
$a (PubMed)33950270
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Shah, Chetan C $u Pediatric Radiology, Wolfson Children's Hospital, Nemours Children's Health System, 800 Prudential Drive, Jacksonville, FL, 32207, USA. Chetan.Shah@nemours.org
245    10
$a Safety and diagnostic efficacy of gadoteridol for magnetic resonance imaging of the brain and spine in children 2 years of age and younger / $c CC. Shah, MV. Spampinato, HA. Parmar, OA. Raslan, P. Tomà, DDM. Lin, J. Vymazal, C. Colosimo, DS. Enterline
520    9_
$a BACKGROUND: Neonates and young children require efficacious magnetic resonance imaging (MRI) examinations but are potentially more susceptible to the short- and long-term adverse effects of gadolinium-based contrast agents due to the immaturity of their body functions. OBJECTIVE: To evaluate the acute safety and diagnostic efficacy of gadoteridol (ProHance) for contrast-enhanced MRI of the central nervous system (CNS) in children ≤2 years of age. MATERIALS AND METHODS: One hundred twenty-five children ≤2 years old (including 57 children <6 months old) who underwent contrast-enhanced MRI of the CNS with gadoteridol at 0.1 mmol/kg body weight were retrospectively enrolled at five imaging centers. Safety data were assessed for acute/subacute adverse events in the 48 h following gadoteridol administration and, when available, vital signs, electrocardiogram (ECG) and clinical laboratory values obtained from blood samples taken from 48 h before until 48 h following the MRI exam. The efficacy of gadoteridol-enhanced MRI compared to unenhanced MRI for disease diagnosis was evaluated prospectively by three blinded, unaffiliated readers. RESULTS: Thirteen changes of laboratory values (11 mild, 1 moderate, 1 unspecified) were reported as adverse events in 7 (5.6%) patients. A relationship to gadoteridol was deemed possible though doubtful for two of these adverse events in two patients (1.6%). There were no clinical adverse events, no serious adverse events and no clinically meaningful changes in vital signs or ECG recordings. Accurate differentiation of tumor from non-neoplastic disease, and exact matching of specific MRI-determined diagnoses with on-site final diagnoses, was achieved in significantly more patients by each reader following the evaluation of combined pre- and post-contrast images compared to pre-contrast images alone (84.6-88.0% vs. 70.9-76.9%; P≤0.006 and 67.5-79.5% vs. 47.0-66.7%; P≤0.011, respectively). CONCLUSION: Gadoteridol at 0.1 mmol/kg body weight is safe, well tolerated and effective for contrast-enhanced MRI of the CNS in children ≤2 years of age.
650    _2
$a mozek $7 D001921
650    12
$a nádory mozku $7 D001932
650    _2
$a předškolní dítě $7 D002675
650    _2
$a kontrastní látky $x škodlivé účinky $7 D003287
650    _2
$a gadolinium $x škodlivé účinky $7 D005682
650    12
$a heterocyklické sloučeniny $x škodlivé účinky $7 D006571
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    12
$a organokovové sloučeniny $x škodlivé účinky $7 D009942
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
700    1_
$a Spampinato, Maria Vittoria $u Medical University of South Carolina, Charleston, SC, USA
700    1_
$a Parmar, Hemant A $u C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI, USA
700    1_
$a Raslan, Osama A $u Davis Medical Center, University of California, Sacramento, CA, USA
700    1_
$a Tomà, Paolo $u Bambino Gesù Children's Hospital, Rome, Italy
700    1_
$a Lin, Doris D M $u Johns Hopkins University School of Medicine, Baltimore, MD, USA
700    1_
$a Vymazal, Josef $u Department of Radiology, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Colosimo, Cesare $u Insitute of Radiology, Radiodiagnostica e Neuroradiologia, Fondazione Policlinico Universitario "A. Gemelli," Universita Cattolica del Sacro Cuore, Rome, Italy
700    1_
$a Enterline, David S $u Duke University School of Medicine, Durham, NC, USA
773    0_
$w MED00003740 $t Pediatric radiology $x 1432-1998 $g Roč. 51, č. 10 (2021), s. 1895-1906
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33950270 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145800 $b ABA008
999    __
$a ok $b bmc $g 1751352 $s 1155006
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 51 $c 10 $d 1895-1906 $e 20210505 $i 1432-1998 $m Pediatric radiology $n Pediatr Radiol $x MED00003740
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...